Gossweiler AG

No ORCID on file · 1 paper in corpus · active 2025
2025
A randomized, double blind, placebo-controlled pilot study to assess the efficacy of erenumab in individuals with temporomandibular disorder.
Journal of oral & facial pain and headache ·doi:10.22514/jofph.2025.027

BackgroundErenumab has proven efficacious in treating migraine headache. Temporomandibular disorder (TMD) is a painful disorder which has high co-occurrence rates with migraine. We hypothesized that erenumab-aooe may also be beneficial in r…